Sanofi and Regeneron Pharmaceuticals won a notable victory on Thursday when a federal appeals court reversed a ban on the sale of their pricey cholesterol medicine and ordered a new trial to decide a bitter patent dispute with Amgen, their only rival in a potentially lucrative market.
The appeals court permanently removed an injunction that had actually been suspended several months ago. It would have prevented Sanofi and Regeneron from marketing Praluent, a newer type of cholesterol medicine. The injunction was initially granted by a lower court after a jury last year found their drug infringed on patents held by Amgen, which sells a competing treatment called Repatha.
About the Author Reprints
